A compounded dual GIP/GLP-1 medicine made for one patient, used in physician-supervised metabolic care. It acts on two gut-hormone receptors involved in appetite and blood sugar. Not FDA-approved; prescribed only when medically necessary. Nothing is prescribed unless a licensed physician determines it is appropriate for you.
Tirzepatide acts on two receptors — GIP and GLP-1 — rather than one, which is why it is called a dual agonist. Those pathways are part of how the body handles appetite signalling and blood sugar. This is a compounded preparation made for an individual patient by a state-licensed 503A pharmacy, used within physician-supervised metabolic care.
A weekly injection, prescribed only where a licensed physician determines a compounded preparation is medically necessary for you. It is not a copy of an FDA-approved medicine and has not been reviewed by the FDA.
Raise any personal or family history of thyroid cancer or endocrine tumours, pancreatitis, gallbladder or kidney disease, and every other medicine you take. Ask how the routine is followed and what follow-up looks like.
Educational information only. It is not medical advice and does not describe results you should expect. A licensed physician decides what, if anything, is appropriate for you.
For your consultation
Saving a treatment asks your physician to consider it during your review. It is not an order, a purchase, or a guarantee of prescription — your physician reviews your history and decides what, if anything, is appropriate. Not everyone will qualify.
Take these to my consultation →